Prediction of the reversibility of the ultrasound-induced blood-brain barrier opening using passive cavitation detection with magnetic resonance imaging validation

2013 ◽  
Vol 134 (5) ◽  
pp. 4183-4183 ◽  
Author(s):  
Tao Sun ◽  
Gesthimani Samiotaki ◽  
Elisa E. Konofagou
Keyword(s):  
Magnetic Resonance Imaging ◽  
Magnetic Resonance ◽  
Blood Brain Barrier ◽  
Brain Barrier ◽  
Resonance Imaging ◽  
Blood Brain ◽  
Passive Cavitation Detection ◽  
Barrier Opening ◽  
Cavitation Detection ◽  
Blood Brain Barrier Opening

scholarly journals PET-MRI nanoparticles imaging of blood–brain barrier damage and modulation after stroke reperfusion

2020 ◽  
Vol 2 (2) ◽  
Author(s):  
Justine Debatisse ◽  
Omer Faruk Eker ◽  
Océane Wateau ◽  
Tae-Hee Cho ◽  
Marlène Wiart ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Magnetic Resonance ◽  
Ischaemic Stroke ◽  
Blood Brain Barrier ◽  
Acute Ischaemic Stroke ◽  
Brain Parenchyma ◽  
Brain Barrier ◽  
Resonance Imaging ◽  
Blood Brain ◽  
Blood Brain Barrier Damage

Abstract In an acute ischaemic stroke, understanding the dynamics of blood–brain barrier injury is of particular importance for the prevention of symptomatic haemorrhagic transformation. However, the available techniques assessing blood–brain barrier permeability are not quantitative and are little used in the context of acute reperfusion therapy. Nanoparticles cross the healthy or impaired blood–brain barrier through combined passive and active processes. Imaging and quantifying their transfer rate could better characterize blood–brain barrier damage and refine the delivery of neuroprotective agents. We previously developed an original endovascular stroke model of acute ischaemic stroke treated by mechanical thrombectomy followed by positron emission tomography-magnetic resonance imaging. Cerebral capillary permeability was quantified for two molecule sizes: small clinical gadolinium Gd-DOTA (<1 nm) and AGuIX® nanoparticles (∼5 nm) used for brain theranostics. On dynamic contrast-enhanced magnetic resonance imaging, the baseline transfer constant Ktrans was 0.94 [0.48, 1.72] and 0.16 [0.08, 0.33] ×10−3 min−1, respectively, in the normal brain parenchyma, consistent with their respective sizes, and 1.90 [1.23, 3.95] and 2.86 [1.39, 4.52] ×10−3 min−1 in choroid plexus, confirming higher permeability than brain parenchyma. At early reperfusion, Ktrans for both Gd-DOTA and AGuIX® nanoparticles was significantly higher within the ischaemic area compared to the contralateral hemisphere; 2.23 [1.17, 4.13] and 0.82 [0.46, 1.87] ×10−3 min−1 for Gd-DOTA and AGuIX® nanoparticles, respectively. With AGuIX® nanoparticles, Ktrans also increased within the ischaemic growth areas, suggesting added value for AGuIX®. Finally, Ktrans was significantly lower in both the lesion and the choroid plexus in a drug-treated group (ciclosporin A, n = 7) compared to placebo (n = 5). Ktrans quantification with AGuIX® nanoparticles can monitor early blood–brain barrier damage and treatment effect in ischaemic stroke after reperfusion.

Adverse effects of erenumab on cerebral proliferative angiopathy: A case report

Cephalalgia ◽  
2020 ◽  
pp. 033310242095048
Author(s):  
Laura L Lehman ◽  
Rebecca Bruccoleri ◽  
Amy Danehy ◽  
Julie Swanson ◽  
Christine Mrakotsky ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
White Matter ◽  
Magnetic Resonance ◽  
Blood Brain Barrier ◽  
Vascular Malformations ◽  
Hippocampal Sclerosis ◽  
White Matter Injury ◽  
Brain Barrier ◽  
Resonance Imaging ◽  
Blood Brain

Background Cerebral proliferative angiopathy is a vascular malformation associated with compromised blood-brain barrier and with migraine-like headache. Treating blood-brain barrier-compromised patients with erenumab, an anti-calcitonin gene-related peptide receptor monoclonal antibody, may be risky. Case We describe a case of a 22-year-old chronic migraine patient with cerebral proliferative angiopathy who presented to our hospital in status epilepticus 2 d after his first dose of erenumab. Serial magnetic resonance imaging (MRI) studies demonstrated progressive areas of diffusion restriction including the brain tissue adjacent to the cerebral proliferative angiopathy, bilateral white matter and hippocampi. His 6-month post-presentation magnetic resonance imaging was notable for white matter injury, encephalomalacia surrounding cerebral proliferative angiopathy and bilateral hippocampal sclerosis. He remains clinically affected with residual symptoms, including refractory epilepsy and cognitive deficits. Conclusion The evidence presented in this case supports further investigation into potential deleterious side effects of erenumab in patients with compromised blood-brain barrier, such as individuals with intracranial vascular malformations.

Blood‐brain barrier dysfunction in canine epileptic seizures detected by dynamic contrast‐enhanced magnetic resonance imaging

Epilepsia ◽  
2019 ◽  
Vol 60 (5) ◽  
pp. 1005-1016 ◽  
Author(s):  
Erez Hanael ◽  
Ronel Veksler ◽  
Alon Friedman ◽  
Guy Bar‐Klein ◽  
Vladimir V. Senatorov ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Magnetic Resonance ◽  
Blood Brain Barrier ◽  
Epileptic Seizures ◽  
Brain Barrier ◽  
Resonance Imaging ◽  
Barrier Dysfunction ◽  
Dynamic Contrast Enhanced ◽  
Blood Brain ◽  
Contrast Enhanced

scholarly journals Specific Targeting of Brain Tumors with an Optical/Magnetic Resonance Imaging Nanoprobe across the Blood-Brain Barrier

2009 ◽  
Vol 69 (15) ◽  
pp. 6200-6207 ◽  
Author(s):  
Omid Veiseh ◽  
Conroy Sun ◽  
Chen Fang ◽  
Narayan Bhattarai ◽  
Jonathan Gunn ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Magnetic Resonance ◽  
Brain Tumors ◽  
Blood Brain Barrier ◽  
Brain Barrier ◽  
Resonance Imaging ◽  
Specific Targeting ◽  
Blood Brain
Sign in / Sign up

Export Citation Format

Share Document